The news you want - the way you want it
Noctura 400 mask

Non invasive prevention and treatment for Diabetic Retinopathy & Diabetic Macular Oedema

Diabetic retinopathy and diabetic macular oedema are two of the first complications of diabetes to appear because of the way high blood glucose damages blood vessels. The tiny blood vessels in the eyes are especially vulnerable.

In the US, diabetic retinopathy is responsible for most cases of vision loss in diabetics and is a leading cause of blindness in working-age adults. Diabetic macular oedema, a swelling of the central area of the retina, occurs as a result of diabetic retinopathy.

Laser treatments are effective when the damage is discovered early enough. More advanced disease requires expensive injections of ant-VGEF agents like Avastin, Eylea, and Lucentis to halt or at least slow down the progression of the disease process

A company called Polyphotonix Medical has created a non-invasive product for both diabetic retinopathy and diabetic macular edema.

It’s an eye mask worn at night named the Noctura 400 Sleep Mask, and it is a monitored ophthalmic treatment that they say can be used to slow, stop, or reverse the effects of retinopathy.

The mask is currently available and licensed for clinical use in the UK, Europe, and in various parts of the Middle East.

How Does the Noctura 400 Work? A soft fabric mask contains a pod that delivers a dose of light therapy while a patient is sleeping. The creators, Polyphotonix, say that it reduces the oxygen demand of the retina during the night lowering the risk of retinal hypoxia–a key contributing factor in the development of retinopathy in patients with diabetes.

The Noctura 400 has been submitted to the FDA and is still awaiting approval. [To learn more about the device or where to get in other countries, visit]

One Man’s Positive Experience With the Noctura 400:

Patrick McCrosson lives in Boston, Massachusetts and has lived with type 1 diabetes for nearly 40 years. He was diagnosed with pre-proliferative retinopathy in April of 2016 and told by his ophthalmologist that if it got worse, he’d require laser treatment.

Patrick started a Facebook group called "Diabetes Retinopathy and Eye Solution" to gather information about what treatments were available. He learned that as many as 50% of the patients treated with laser therapy lose their peripheral, color, and night vision. A frightening prospect! A member of the group, Jacob from Chicago, raved about the Nocura 400 mask. Jacob was the first US patient to fly to the UK to purchase one. McCrosson researched the Noctura 400 and found only positive reviews for it. 5 days later he booked his ticket.

Patrick writes that “Polyphotonix and their distributor, the Outside Clinic in Swindon, England gave me 5-star service and made it so easy to purchase once I was in London. With beneficial FDA laws in place, I only had to fly to London once to purchase the mask as they can now be shipped to me every six months.”

McCrosson writes that “Getting used to the green light took about five days and now when I put it on before bed, I barely notice the green shining in my eyes as they have adjusted. Wearing the mask itself took less than two weeks to get adjusted to as I would take it off in the middle of the night. I found that tightening it and telling myself before bed not to remove it, solved that issue.”

Three weeks after getting the mask, McCrosson went back to his Ophthalmologist for a follow-up. He was hoping to learn that his retinopathy had not progressed. He was not expecting the Noctura 400 to have helped so soon and was “in complete surprise when my doctor told me my eyes were looking great and that the micro-aneurysms had reduced in both eyes, but especially in my right eye.”

McCrosson writes that “Members of my Facebook group using the mask have all reduced bleeds, lasers, injections, visits to the eye doctor, costs and anxiety. Several have reported improved vision. One enthusiastic member, Sysy Morales says, "I am excited to share that I went from 20/100 vision down to 20/70 for the first time in 35 years! To date, my eye disease has not progressed to proliferative retinopathy, and I have escaped lasers and eye injections. The Noctura 400 has restored my faith in the future, and I am excited to tell people with diabetes across the world that we don't have to suffer anymore.”

Sysy Morales, for Diabetes Daily

[Editor's note: After reading about the Noctura 400 Sleep Mask, I decided to give it a try myself. I've been getting injections for diabetic macular edema, every six weeks, for close to three years. The great people at Polyphotonix agreed to send a mask to me in Australia. I've worn it four nights now. It does take some getting used to. My next appointment with my ophthalmologist is in five days, and I can't wait to find out whether or not he can see any improvement.]

Learn more about the Noctura 400


“Alternative” medicine’s toll on cancer patients

With a death rate up to 5X higher, researchers hope the data will guide patients to effective treatments.

Unproven alternative treatments are risky. Some carry the risk of direct harm, such as improperly diluted homeopathic chemicals, blinding stem cell injections, contaminated supplements, or tainted placenta pills. And others, such as magic healing crystals and useless detoxes, may risk indirect harm by taking the place of evidence-based treatments.

However obvious the risks, measuring them has been tricky. For one thing, patients aren’t always eager to provide data, let alone admit to their doctors that they’ve ditched conventional therapies. But, by digging into the National Cancer database, researchers at Yale have finally quantified one type of risk for cancer patients—the risk of death. And the results are grim.

Those who skipped or delayed conventional treatment to use alternative ones had as much as a 5.7-fold increased risk of dying within five years than those who stuck with orthodox medicine, the researchers reported in the Journal of the National Cancer Institute. Though the study was small and had several gaps—including not knowing the types of alternative treatments patients had tried—the researchers hope that it spurs discussion and “greater scrutiny of the use of alternative medicine for the initial treatment of cancer.”

For the analysis, researchers, led by Skyler Johnson, focused on the four most prevalent types of cancer in the US between 2004 and 2013: breast, lung, colorectal, and prostate. Mining the database, they sought cases of patients who received no conventional treatment and whose medical records contained codes for alternative management. Those treatments were defined as “other-unproven: cancer treatments.' The researchers ended up 280 records of patients who chose alternative medicine over conventional therapies. Those patients tended to be female, young, have high education and income, and have few complicating health conditions.

For comparison, the researchers matched each of those patients with two other patients diagnosed in the same year, had matching age, race, disease, disease stage, and insurance type—but had opted for conventional treatments. Those treatments were defined as
“chemotherapy, radiotherapy, surgery, and hormone therapy.” Together, the researchers analyzed medical records of 840 patients tracked for a median of 66 months.

Overall, those in the alternative treatment group were 2.5 times more likely to die within five years of treatment than the conventional group. But, that figure is dragged down by cases of prostate cancer, which tend to progress slowly. The researchers found no statistically significant difference in mortality risks among prostate cancer patients regardless of what types of treatments they chose.

Among patients with breast cancer, alternative medicine users were 5.7 times more likely to die within five years than their counterparts. Those with colorectal cancer were 4.6 times more likely to die if they used alternative medicine. And those with lung cancer who opted for alternative medicine were 2.2 times more likely to die.

The study has limitations, the researchers caution. Most notably, it’s an observational study, so it cannot determine if alternative therapies—or lack of evidence-based conventional ones—are the actual cause of the drops in survival rates. That said, the researchers also don’t know if some of the patients who initially opted for alternative medicine later turned to conventional treatments. Thus, it’s possible that the survival rates may be even worse for those who rely solely on alternative therapy. Last, because of the vague coding, the researchers don’t know what kinds of treatments patients were trying and if some are more dangerous than others.

Still, the researchers hope that the study raises flags with caregivers when their patients want to swap conventional treatments for alternative ones.

Journal of the National Cancer Institute, 2017. DOI: 10.1093/jnci/djx145 (About DOIs).

Ebola vaccine proves effective, final trial results show

An experimental Ebola vaccine has triumphed in West Africa.

Of 5,837 people in Guinea who received a single shot of the vaccine, rVSV-ZEBOV, in the shoulder, none became infected with the virus 10 to 84 days after vaccination. That’s “100% protection,” researchers report December 22 in the Lancet.

World Health Organisation researcher Ana Maria Henan-Restrepo and colleagues tested a “ring vaccination” approach, by immediately vaccinating family members and other contacts of people infected with Ebola. This strategy seemed to staunch the virus’s spread. Among 4,507 people never vaccinated or who got a delayed vaccine, 23 contracted Ebola.

The findings echo preliminary results reported in 2015, and offer a promising line of defense for future outbreaks. But scientists still do not know how long-lasting the vaccine’s protection would be.

In late 2013, West Africa saw the beginning of what would become the largest Ebola outbreak in history, with more than 11,300 deaths reported, and 28,616 cases in Guinea, Sierra Leone and Liberia. Since then, scientists have been racing to create a safe and effective vaccine.

Science News

Why consumers maintain complementary and alternative medicine use

Why has it been increasing in popularity (and is it, really?). Is it slick marketing, relaxed regulations, scientific illiteracy, a gullible media, or the failures of mainstream medicine? You can probably guess I think it’s all of these things to some degree.

This study suggests that experiences of conventional medicine are of limited importance after the decision to initiate CAM. Experiences of CAM were foremost in our consumers' decisions to maintain or stop specific CAM therapies. Maintenance of CAM could occur even if consumers' experiences were not entirely positive. Our findings provide novel, systematic insights that will be of particular interest to practitioners who want to support consumers as they decide whether to maintain CAM use.

PubMed Science Based Medicine

A stick-on patch that could keep tabs on stroke patients at home

AUSTIN, Texas — Stretchy sensors that stick to the throat could track the long-term recovery of stroke survivors.

These new Band-Aid‒shaped devices contain motion sensors that detect muscle movement and vocal cord vibrations. That sensor data could help doctors diagnose and monitor the effectiveness of certain treatments for post-stroke conditions like difficulty swallowing or talking, researchers reported February 17 in a news conference at the annual meeting of the American Association for the Advancement of Science. Up to 65 percent of stroke survivors have trouble swallowing, and about a third of survivors have trouble carrying on conversations.

The devices can monitor speech patterns more reliably than microphones by sensing tissue movement rather than recording sound. “You don’t pick up anything in terms of ambient noise,” says study coauthor John Rogers, a materials scientist and bioengineer at Northwestern University in Evanston, Ill. “You can be next to an airplane jet engine. You’re not going to see that in the [sensor] signal.”

Developed by Rogers’ team, the sensors have built-in 12-hour rechargeable batteries and continually stream motion data to a smartphone. Researchers are now testing the sensors with real stroke patients to see how the devices can be made more user-friendly. For instance, Rogers’ team realized that patients were unlikely to wear sensors that were too easily visible. By equipping the patches with more sensitive motion sensors, they can be worn lower on a person’s neck, hidden behind a buttoned-up shirt, and still pick up throat motion.

These kinds of sensors could also track the recovery of neck cancer patients, who commonly develop swallowing and speaking problems caused by radiation therapy and surgery, Rogers says. The devices can also measure breathing and heart rates to monitor sleep quality and help diagnose sleep apnea. Rogers expects this wearable tech to be ready for widespread use within the next year or two.

Science News

Website invites you to probe a 3-D human brain

The Society for Neuroscience and other organisations have long sponsored the website, which has basic information about how the human brain functions.

NOTE: The articles on these pages are mostly nonsense. For God’s sake, do not believe or attempt any of them! They are here as a testament to the stupidity and gullibility of humans, and proof that snake oil salesmen are still alive and prospering in the 21st century